Clinical trials: Squamous Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer
Advanced non-small-cell lung cancer (NSCLC) patients without epidermal growth factor receptor (EGFR) mutations show a poor prognosis.
- Trial name
- NCT01623102
- Testing
- cisplatin and gemcitabine combination with Bevacizumab, Gemcitabine combined with cisplatin chemotherapy
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Non-small Cell Lung Cancer
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients…
- Trial name
- NCT05746481
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Liza Villaruz, MD
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Healthy, no Evidence of Disease, Lung Cancer
Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants
RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00899457
- Testing
- proteomic profiling, biologic sample preservation procedure, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- Trial name
- POD1UM-304 (NCT04205812)
- Testing
- Retifanlimab, Pemetrexed, Cisplatin
- Where
- 140 sites in United States, Brazil and 15 more
- Volunteers
- 583 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.
- Trial name
- CANOPY-1 (NCT03631199)
- Testing
- canakinumab, pembrolizumab, carboplatin
- Where
- 152 sites in United States, Argentina and 39 more
- Volunteers
- 673 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00287963
- Testing
- topotecan hydrochloride, vinorelbine tartrate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Lung Cancer
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00970684
- Testing
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nathan Pennell, MD, PhD
Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
Chest malignant solid tumor (mainly lung and esophageal cancer) is a common malignant tumor that seriously threatens the health of residents in China.
- Trial name
- NCT05044728
- Testing
- Anti-PD-1 antibody combined with Paclitaxel and carboplatin., Surgical treatment stage
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
NSCLC Stage IV
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung…
- Trial name
- PCA (NCT04136535)
- Testing
- Pemetrexed, Carboplatin, Anlotinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Fudan University
Solid Tumor, Colorectal Cancer (CRC)
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
- Conditions
- Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- ODIN (NCT07151040)
- Testing
- TH9619
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 43 people
- Sponsor
- One-carbon Therapeutics AB
NSCLC
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
- Trial name
- NCT06246110
- Testing
- EIK1001, Pembrolizumab, Paclitaxel
- Where
- 38 sites in United States
- Volunteers
- 70 people
- Sponsor
- Eikon Therapeutics
Squamous-Cell Non-Small-Cell Lung Cancer
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and combination with other anti-cancer therapies, and to determine the recommended phase 3 dose of bemarituzumab in…
- Trial name
- FORTITUDE-201 (NCT05267470)
- Testing
- Bemarituzumab, Docetaxel, Pembrolizumab
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 74 people
- Sponsor
- Amgen
Imaging, Colorectal Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor…
- Conditions
- Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
- Trial name
- DUNP19 (NCT07272642)
- Testing
- LNTH-2403
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Radiopharm Theranostics, Ltd
Lung Cancer
Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00002623
- Testing
- carboplatin, cisplatin, conventional surgery
- Where
- 30 sites in Belgium, France and 3 more
- Volunteers
- 640 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell, Non-small-cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976362
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Non-small Cell Lung Cancer
Exhaled Breath Particles in Lung Cancer
Lung cancer (CaP) is the leading cause of cancer related deaths on a global level. Early diagnosis is vital for survival and life quality of the affected patients, yet lung cancer is often diagnosed at advanced stages, causing…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Cancer
- Trial name
- NCT05395611
- Testing
- EBPcollected using the PExA device.
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Lund University Hospital
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.